Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Summary

Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.

Timeline

Start

2023-05-30

Primary completion

2025-08-14

Completion

2025-08-14

Drugs

Indications